Development of production and purification processes of recombinant fragment of pneumococcal surface protein A in Escherichia coli using different carbon sources and chromatography sequences

Applied Microbiology and Biotechnology

Volumn 94, Issue 3, 2012, Pages 683-694

  Carvalho, Rimenys Junior ^a   Cabrera Crespo, Joaquin ^a   Tanizaki, Martha Massako ^a   Gonçalves, Viviane Maimoni ^a  

^a INSTITUTO BUTANTAN   (Brazil)

Author keywords

Escherichia coli; High cell density; Liquid chromatography; PspA; Recombinant protein purification; Streptococcus pneumoniae

Indexed keywords

ALPHA-HELIX; ANION EXCHANGE; CARBON SOURCE; CATION EXCHANGE CHROMATOGRAPHY; CELL DISRUPTION; CONJUGATE VACCINE; DOWNSTREAM PROCESS; DRY CELLS; E. COLI; FED-BATCH PRODUCTION; HIGH CELL DENSITY; HIS-TAGGED PROTEINS; METAL AFFINITY; NEW DESIGN; PSPA; PURIFICATION PROCESS; RECOMBINANT PROTEIN PURIFICATION; SCALABLE PRODUCTION; SECONDARY STRUCTURES; STREPTOCOCCUS PNEUMONIAE; SURFACE PROTEINS;

CARBON; CELL CULTURE; CELLS; ESCHERICHIA COLI; GLUCOSE; GLYCEROL; LIQUID CHROMATOGRAPHY; PURIFICATION; VACCINES;

RECOMBINANT PROTEINS;

BACTERIAL PROTEIN; GLUCOSE; GLYCEROL; MEMBRANE PROTEIN; PNEUMOCOCCAL SURFACE PROTEIN A; UNCLASSIFIED DRUG;

CARBON; COLIFORM BACTERIUM; CONCENTRATION (COMPOSITION); GLUCOSE; ION EXCHANGE; LIQUID CHROMATOGRAPHY; PROTEIN; VACCINE; VIRULENCE;

ARTICLE; BACTERIAL VIRULENCE; CARBON SOURCE; CATION EXCHANGE; CELL DENSITY; CELL DISRUPTION; CELL VIABILITY; CHROMATOGRAPHY; CIRCULAR DICHROISM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWNSTREAM PROCESSING; ESCHERICHIA COLI; ION EXCHANGE CHROMATOGRAPHY; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN PURIFICATION; PROTEIN SECONDARY STRUCTURE; PROTEIN SYNTHESIS;

BACTERIAL PROTEINS; BIOTECHNOLOGY; CARBON; CHROMATOGRAPHY; CULTURE MEDIA; ESCHERICHIA COLI; RECOMBINANT PROTEINS; STREPTOCOCCUS PNEUMONIAE;

ESCHERICHIA COLI; STREPTOCOCCUS PNEUMONIAE;

EID: 84862702294     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-011-3649-9     Document Type: Article

References (48)

1. Abeyta M, Hardy GG, Yother J (2003) Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae. Infect Immun 71:218-225. doi:10.1128/IAI.71.1.218-225.2003 (Pubitemid 36026023)
2. Ansaldi F, De Florentiis D, Canepa P, Durando P, Bassetti M, Icardi G (2010) Serotype replacement in Streptococcus pneumoniae after conjugate vaccine introduction: impact, doubts and perspective for new vaccines. Rev Med Microbiol 21:56-64. doi:10.1097/MRM.0b013e32833a345f
3. Ansenjo JA, Andrews BA (2008) Protein purification using chromatography: selection of type, modelling and optimization of operating conditions. J Mol Recognit 22:65-76. doi:10.1002/jmr.898
4. Azevedo AM, Gomes AG, Borlido L, Santos IF, Prazeres DM, Aires-Barros MR (2010) Capture of human monoclonal antibodies from a clarified cell culture supernatant by phenyl boronate chromatography. J Mol Recognit 23:569-576. doi:10.1002/jmr.1068
5. Babaeipour V, Shojaosadati SA, Khalilzadeh R, Maghsoudi N, Tabandeh F (2008) A proposed feeding strategy for the overproduction of recombinant proteins in Escherichia coli. Biotechnol Appl Biochem 49:141-147. doi:10.1042/BA20070089 (Pubitemid 351271078)
6. Balbas P (2001) Understanding the art of producing protein and nonprotein molecules in Escherichia coli. Mol Biotechnol 19:251-267. doi:10.1385/MB:19:3: 251 (Pubitemid 33063507)
7. Baril L, Dietemann J, Essevaz-Roulet M, Béniguel L, Coan P, Briles DE, Guy B, Cozon G (2006) Pneumococcal surface protein A (PspA) is effective at eliciting T cell mediated responses during invasive pneumococcal disease in adults. Clin Exp Immunol 145:277-286. doi:10.1111/j.1365-2249.2006.03148.x (Pubitemid 44060118)
8. Bogaert D, Hermans PW, Adrian PV, Rumke HC, de Groot R (2004) Pneumococcal vaccines: an update on current strategies. Vaccine 22:2209-2220. doi:10.1016/j.vaccine.2003.11.038 (Pubitemid 38626060)
9. Brandileone MC, Andrade AL, Teles EM, Zanella RC, Yara TI, Di Fabio JL, Hollingshead SK (2004) Typing of pneumococcal surface protein A (PspA) in Streptococcus pneumoniae isolated during epidemiological surveillance in Brazil: towards novel pneumococcal protein vaccines. Vaccine 22:3890-3896. doi:10.1016/j.vaccine.2004.04.009 (Pubitemid 39213965)
10. Briles DE, Hollingshead SK, Swiatlo E, Brooks-Walter A, Szalai A, Virolainen A, McDaniel LS, Benton KA, White P, Prellner K, Hermansson A, Aerts PC, Van Dijk H, Crain MJ (1997) PspA and PspC: their potential for use as pneumococcal vaccines. Microb Drug Resist 3:401-408. doi:10.1089/mdr.1997.3.401 (Pubitemid 28065092)
11. Briles DE, Hollingshead SK, Brooks-Walter A, Nabors GS, Ferguson L, Schilling M, Gravenstein S, Braun P, King J, Swift A (2000a) The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. Vaccine 18:1707-1711. doi:10.1016/S0264-410X(99)00511-3 (Pubitemid 30109533)
12. Briles DE, Hollingshead SK, Nabors GS, Paton JC, Brooks-Walter A (2000b) The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae. Vaccine 19:S87-S95. doi:10.1016/S0264-410X(00) 00285-1 (Pubitemid 32121727)
13. Choi JH, Keum KC, Lee SY (2006) Production of recombinant proteins by high cell density culture of Escherichia coli. Chem Eng Sci 61:876-885. doi:10.1016/j.ces.2005.03.031 (Pubitemid 41650182)
14. Christodoulou E, Duffner F, Vorgias CE (2001) Overexpression, purification, and characterization of a thermostable chitinase (Chi40) from Streptomyces thermoviolaceus OPC-520. Protein Expr Purif 23:97-105. doi:10.1006/prep.2001.1490 (Pubitemid 32930984)
15. De Mey M, De Maeseneire S, Soetaert W, Vandamme E (2007) Minimizing acetate formation in E. coli fermentations. J Ind Microbiol Biotechnol 34:689-700. doi:10.1007/s10295-007-0244-2 (Pubitemid 47622241)
16. Ferreira DM, Darrieux M, Silva DA, Leite LCC, Ferreira JMC Jr, Ho PL, Miyaji EN, Oliveira MLS (2009) Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice. Clin Vaccine Immunol 16:636-645. doi:10.1128/CVI.00395-08
17. Geng X, Wang L (2008) Liquid chromatography of recombinant proteins and protein drugs. J Chromatogr B Anal Technol Biomed Life Sci 866:133-153. doi:10.1016/j.jchromb.2008.01.041
18. Gnoth S, Jenzsch M, Simutis R, Lubbert A (2008) Control of cultivation processes for recombinant protein production: a review. Bioprocess Biosyst Eng 31:21-39. doi:10.1007/s00449-007-0163-7 (Pubitemid 350276242)
19. Gottschalk U (2008) Bioseparation in antibody manufacturing: the good, the bad and the ugly. Biotechnol Prog 24:496-503. doi:10.1021/bp070452g (Pubitemid 351832703)
20. Goyal D, Sahni G, Sahoo DK (2009) Enhanced production of recombinant streptokinase in Escherichia coli using fed-batchculture. Bioresour Technol 100:4468-4474. doi:10.1016/j.biortech.2009.04.008
21. Hansen R, Eriksen NT (2007) Activity of recombinant GST in Escherichia coli grown on glucose and glycerol. Process Biochem 42:1259-1263. doi:10.1016/j.procbio.2007.05.022 (Pubitemid 47089068)
22. Hewitt CJ, Nienow AW (2007) The scale-up of microbial batch and fed-batch fermentation processes. Adv Appl Microbiol 62:105- 135. doi:10.1016/S0065- 2164(07)62005-X (Pubitemid 47380497)
23. Hollingshead SK, Becker R, Briles DE (2000) Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun 68:5889-5900
24. Hortsch R, Weuster-Botz D (2010) Growth and recombinant protein expression with Escherichia coli in different batch cultivation media. Appl Microbiol Biotechnol 90:69-76. doi:10.1007/s00253-010-3036-y
25. Jedrzejas MJ, Lamani E, Becker RS (2001) Characterization of selected strains of pneumococcal surface protein A. J Biol Chem 276:33121-33128. doi:10.1074/jbc.M103304200
26. Kamerling JP (2000) Pneumococcal polysaccharides: a chemical view. In: Tomasz A (ed) Streptococcus pneumoniae molecular biology and mechanisms of disease. Mary Ann Liebert Publishers Inc., New York, pp 81-114
27. Kelly SM, Jess TJ, Price NC (2005) How to study proteins by circular dichroism. Biochim Biophys Acta 1751:119-139. doi:10.1016/j.bbapap.2005.06.005 (Pubitemid 41112231)
28. Laemmli UK, Beguin F, Gujer-Kellenberger G (1970) A factor preventing the major head protein of bacteriophage T4 from random aggregation. J Mol Biol 47:69-74. doi:10.1016/0022-2836(70)90402-X
29. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275
30. Martinez K, de Anda R, Hernandez G, Escalante A, Gosset G, Ramirez OT, Bolivar FG (2008) Coutilization of glucose and glycerol enhances the production of aromatic compounds in an Escherichia coli strain lacking the phosphoenolpyruvate: carbohydrate phosphotransferase system. Microb Cell Fact 7:1. doi:10.1186/1475-2859-7-1 (Pubitemid 351298390)
31. McDonald JR, Ong M, Shen C, Parandoosh Z, Sosnowski B, Bussell S, Houston LL (1996) Large-scale purification and characterization of recombinant fibroblast growth factor-saporin mitotoxin. Protein Expr Purif 8:97-108. doi:10.1006/prep.1996.0079 (Pubitemid 26326218)
32. Mera R, Miller LA, Fritsche TR, Jones RN (2008) Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb Drug Resist 14:101-107. doi:10.1089/mdr.2008.0782
33. Miyaji EN, Ferreira DM, Lopes AP, Brandileone MC, Dias WO, Leite LC (2002) Analysis of serum cross-reactivity and cross-protection elicited by immunization with DNA vaccines against Streptococcus pneumoniae expressing PspA fragments from different clades.
34. Miyaji EN, Dias WO, Tanizaki MM, Leite LC (2003) Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses. FEMS Immunol Med Microbiol 37:53-57. doi:10.1016/S0928-8244(03)00108-1 (Pubitemid 36588928)
35. Nabors GS, Braun PA, Herrmann DJ, Heise ML, Pyle DJ, Gravenstein S, Schilling M, Ferguson LM, Hollingshead SK, Briles DE, Beckera RS (2000) Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine 18:1743-1754 (Pubitemid 30122836)
36. Narang A (2009) Quantitative effect and regulatory function of cyclic adenosine 5'-phosphate in Escherichia coli. J Biosci 34(3):445-463
37. Neijssel OM, Teixeira de Mattos MJ, Tempest DW (1999) Growth yield and energy distribution. In: Neidhardt FC (ed) Escherichia coli and Salmonella: cellular and molecular biology, chapter 107, 2nd edn. ASM, Washington, p 10
38. Noble JB (2001) Scale-up considerations. In: Roe SD (ed) Protein purification techniques, 2nd edn. Oxford University Press, New York, p 262
39. Ochs MM, Bartlett W, Briles DE, Hicks B, Jurkuvenasa A, Lau P, Ren B, Millar A (2008) Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae. Microb Pathog 44:204-214. doi:10.1016/j.micpath.2007.09.007 (Pubitemid 351163528)
40. Oliveira MLS, Miyaji EN, Ferreira DM, Moreno AT, Ferreira PCD, Lima FA, Santos FL, Sakauchi MA, Takata CS, Higashi HG, RawI KFS, Ho PL (2010) Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice. PLoS One 5 (5):e10863. doi:10.1371/journal.pone.0010863
41. Roush DJ, Lu Y (2008) Advances in primary recovery: centrifugation and membrane technology. Biotechnol Prog 24:488-495. doi:10.1021/bp070414x (Pubitemid 351832702)
42. Schmidt SA, Williams SJ, Wang CA, Sornaraj P, James B, Kobe B, Dodds PN, Ellis JG, Anderson PA (2007) Purification of the M flax-rust resistance protein expressed in Pichia pastoris. Plant J 50:1107-1117. doi:10.1111/j.1365-313X. 2007.03104.x (Pubitemid 46904107)
43. Seeger A, Schneppe B, McCarthy JEG, Deckwer WD, Rinas U (1995) Comparison of temperature-induced and isopropyl-beta-D-thiogalacto-pyranoside-induced synthesis of basic fibroblast growth-factor in high-cell-density cultures of recombinant Escherichia coli. Enzyme Microb Technol 17:947-953. doi:10.1016/0141-0229(94)00123-9
44. Shiloach J, Fass R (2005) Growing E. coli to high cell density: a historical perspective on method development. Biotechnol Adv 23:345-357. doi:10.1016/j.biotechadv.2005.04.004 (Pubitemid 40727987)
45. Shukla AA, Hubbard B, Tressel T, Guhan S, Low D (2007) Downstream processing of monoclonal antibodies: application of platform approaches. J Chromatogr B Anal Technol Biomed Life Sci 848:28-39. doi:10.1016/j.jchromb.2006. 09.026 (Pubitemid 46367766)
46. Silva M, Cabrera-Crespo J, Sbrogio-Almeida ME, Miyaji EN, Ho PL, Leite LC, Lopes AP (2007) Optimizing expression of Streptococcus pneumoniae surface protein A, PspA: serocross-reactivity within families of antisera induced against clades 1 and 3. Mol Biotechnol 37:146-154. doi:10.1007/s12033-007-0043-z (Pubitemid 350135891)
47. Son YJ, Bae JY, Chong SH, Lee HS, Mo SH, Kim TY, Choe H (2010) Expression, high cell density culture and purification of recombinant EC-SOD in Escherichia coli. Appl Biochem Biotechnol 162:1585-1598. doi:10.1007/s12010-010- 8940-1
48. Zhao M, Wu M, Guo L, Jiang J, Huang W, Lin X, Zhang Z, Xiang D, Lu H, Zhu S, Yu Y, Moldenhauer A, Han W (2010) Expression, purification, and characterization of a novel soluble form of human delta-like-1. Appl Biochem Biotechnol 160:1415-1427. doi:10.1007/s12010-009-8603-2